Prokaryotics is a start-up biotechnology company resulting from licensing several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the head of the Antimicrobial Early Discovery Unit, to optimize a number of Merck’s early-stage programs. Prokaryotics has negotiated worldwide rights to develop, manufacture and commercialize pre-clinical assets and programs targeting both Gram-negative and Gram-positive bacteria. Prokaryotics is an authentic antibacterial discovery organization committed to bringing forth innovative therapeutics to address the problem of multidrug resistant bacteria and combating the emerging global crisis of antibiotic resistance.